The EGM is a formality; all resolutions are expected to pass given board unanimity. The massive dilution from the already-executed and pending capital raises will continue to pressure the stock. Traders should expect continued weakness as the market absorbs the new supply, and monitor for any clinical catalysts that could offset the dilutive overhang.
Price Chart
Executive Summary
Radiopharm Theranostics filed a 6-K furnishing a notice of an Extraordinary General Meeting (EGM) scheduled for September 11, 2026, to seek shareholder ratification and approval for the massive equity issuance tied to its ~$18.5M multi-tranche capital raise announced July 24, 2026. The EGM seeks to ratify the prior issuance of 408.8M placement shares and 384.5M ADS shares, and to approve the issuance of up to an additional 40M second-tranche shares, ~448.8M attaching options, up to 666.7M SPP shares with matching options, 200M shortfall options, ADR warrants, and agent warrants. This filing is a procedural step to formalize the massive dilution already executed and pending, which is deeply bearish for a ~$41M market cap pre-revenue biotech.
Key Facts
- The EGM seeks to ratify the prior issue of 408,839,531 Placement Shares (issued Aug 3, 2026) and 384,493,800 ADS Shares (issued July 28, 2026).
- Shareholders are asked to approve up to 40,000,000 Second Tranche Placement Shares at $0.015 per share.
- Approval is sought for up to 448,839,531 Placement Attaching Options (exercise price $0.018, expiring July 31, 2029).
- Approval is sought for up to 666,666,667 SPP Shares and 666,666,667 SPP Attaching Options (exercise price $0.018).
- Approval is sought for 200,000,000 Shortfall Options to Trading Capital Management (HK) Ltd.
- Approval is sought for up to 1,281,646 ADR Warrants (exercise price US$3.79 per ADS) and 64,082 Agent Warrants to H.C. Wainwright (exercise price US$3.95).
- The total capital raise is approximately $18.5M, comprising a ~$6.7M placement, ~$5.8M US direct offering, and up to ~$6M SPP.
- The filing follows a 424B5 from July 27, 2026, which raised ~$4.05M at a ~26% discount, signaling urgent capital needs.
Financial Impact
Massive dilution: the capital raise totals approximately $18.5M against a ~$41M market cap. The share issuances already executed and proposed represent hundreds of millions of new shares, with the SPP alone authorizing up to 666.7M new shares. The 424B5 offering was priced at a ~26% discount.
Risk Factors
- Shareholder approval is virtually assured, leading to the full issuance of all proposed shares and options, causing extreme dilution.
- The company is pre-revenue with no disclosed financial results, relying entirely on capital markets for funding.
- The 26% discount on the prior 424B5 offering signals urgency and weak demand at higher prices.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088705 |
| Document: ea0301905-6k_radiopharm.htm | 0001213900-26-088705 |
| Document: 0001213900-26-088705-index-headers.html | 0001213900-26-088705 |
| Document: 0001213900-26-088705-index.html | 0001213900-26-088705 |
| Document: 0001213900-26-088705.txt | 0001213900-26-088705 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9100 (−5.21%) |
Oct 26, 2026 1d ago | 6-K | $0.9485 | awaiting T+5 | — | $0.9100 (−4.06%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9100 (−8.08%) |
Oct 14, 2026 12d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9100 (−15.74%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9100 (−28.35%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9100 (−38.51%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9100 (−43.83%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9100 (+42.11%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9100 (−44.85%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9100 (−54.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers